Particle.news
Clinical Trials Drug Development Cell Therapy Research Funding Viral Vectors Base Editing Clinical Research mRNA Technology Adeno-Associated Virus CRISPR Technology AAV Capsids Messenger RNA Gene-Silencing Technology ELEVIDYS Collaboration RNA Therapy Immunotherapy FDA Approval Transferrin Neurodevelopmental Disorders Stem Cell Research HIV Research Therapeutic Approaches Company Performance In Vivo Products COVID-19 Vaccines RNA Therapeutics Regulation Personalized Medicine Neurological Applications Clinical Development Regulatory Framework Clinical Applications Cellular Response Extracellular Vesicles Experimental Treatments mRNA Applications Organ Replacement Genetic Disorders Preclinical Models uniQure RNA Mechanisms Cancer Treatments Xenotransplantation Duchenne Muscular Dystrophy Exon Skipping RNA Medicines Immunosuppression Prime Medicine Gene Regulation Therapeutic Applications Vaccines RNA Editing RNA Engineering Gene Editing Technologies
A single engineered T cell that recognises GPNMB can attack tumour cells by also targeting the macrophages that support them, requiring further safety studies before human trials.
